Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.73 |
| ▸ | LYN | P07948 | 3/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | EGFR | P00533 | 3/20 | 0.66 |
| ▸ | TEC | P42680 | 3/20 | 0.66 |
| ▸ | BMX | P51813 | 3/20 | 0.66 |
| ▸ | TXK | P42681 | 2/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.66 |
| ▸ | ITK | Q08881 | 2/20 | 0.66 |
| ▸ | FLT3 | P36888 | 2/20 | 0.66 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.66 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.66 |
| ▸ | BLK | P51451 | 2/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.66 |
| ▸ | LATS1 | O95835 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16078937 | 1.00 | BTK (0.73) | BTKLYNLCKEGFRTEC | |
| SCHEMBL23226083 | 0.90 | BTK (0.74) | BTKLYNLCKEGFRTEC | |
| SCHEMBL23226086 | 0.90 | BTK (0.74) | BTKLYNLCKEGFRTEC | |
| SCHEMBL30353041 | 0.90 | BTK (0.71) | BTKLYNLCKEGFRTEC | |
| SCHEMBL16082979 | 0.89 | BTK (0.62) | BTKLYNLCKEGFRITK | |
| SCHEMBL6430702 | 0.89 | BTK (0.76) | BTKLYNLCKEGFRTEC | |
| SCHEMBL28409686 | 0.88 | BTK (0.78) | BTKLYNLCKEGFRTEC | |
| SCHEMBL28409697 | 0.88 | BTK (0.78) | BTKLYNLCKEGFRTEC | |
| SCHEMBL28409758 | 0.88 | BTK (0.78) | BTKLYNLCKEGFRTEC | |
| SCHEMBL18131947 | 0.88 | BTK (0.71) | BTKLYNLCKEGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | claimed |
| EP-2970291-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-11 | — | — | EP | disclosed |
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-9156847-B2 | Processes and intermediates for preparing a medicament | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-13 | — | — | US | disclosed |
| US-9156847-B2 | Processes and intermediates for preparing a medicament | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-13 | — | — | US | disclosed |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139970-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | BTK 1/4885LYN 5/4885LCK 30/4885 |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | BTK 1/4885LYN 7/4885LCK 45/4885 |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | BTK 1/4885LYN 5/4885LCK 30/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | BTK 1/4885LYN 6/4885LCK 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.